Our medicines have a profound impact on lives, because everything we do focuses on that goal

Kyowa Kirin North America is a fully integrated specialty pharmaceutical company, where people work together to understand clinical needs and opportunities for innovation that can result in real advances for patients. Since 2018, the North American organization has received approval from the US Food and Drug Administration (FDA) to market 3 first-in-class medicines – achievements we share with the scientific, medical, and advocacy communities who contributed greatly to the success of these programs.

Our values drive our achievements

At Kyowa Kirin, our Core Values drive us to do everything we can to answer the needs of patients, their families, and medical professionals. We act consistently with these Core Values in mind – Commitment to Life, Innovation, Integrity, and Teamwork/Wa.

Commitment to Life

We strive to contribute to the health and well-being of communities by pursuing advances in life sciences and technologies.

Integrity

We aim to do the right things by being sincere, honest, and ethically consistent in all our business practices and interactions.

Innovation

We transform lives with passion and excitement — challenging the status quo in all that we do.

Teamwork/Wa*

We believe in one for all, and all for one by going beyond boundaries and collaborating with our stakeholders.

*Wa = The Japanese principle of seeking the harmony of the team over personal interests.

Teamwork is at the heart
of our business, and our success

Within our walls and across our industry, collaboration is the way Kyowa Kirin North America does business. Our history of innovation is built on forming and fostering collaborations that accelerate the delivery of new science to patients and heighten the impact of every person involved.

Some collaborations start small and grow to deliver extraordinary results. This has been true throughout Kyowa Kirin’s history. The Kirin Amgen joint venture, which lasted from 1984 until 2017, resulted in the development, worldwide commercialization, and manufacturing of epoetin alfa (marketed as Epogen® in the US, Espo® in Japan), filgrastim (Neupogen® in the US, Gran® in Japan), pegfilgrastim (Neulasta® in the US, G-Lasta® in Japan), and darbepoetin alfa (Aranesp® in the US, NESP® in Japan). Today, Kyowa Kirin continues to enjoy strong, enduring relationships with the La Jolla Institute for Immunology Research and a variety of other business partners focused on advancing discoveries for patients. We also continue to work across our business to find new ideas in need of acceleration.

When you join our team, you become part of an organization that believes in an integrated and collaborative approach to solving problems and achieving goals. We welcome people who share our spirit of innovation and enthusiasm for helping patients to join us.

Kyowa Kirin North America Leadership

Gary Zieziula, MBA
President, North America, Director on Board of Directors
Mr. Gary Zieziula became president, Kyowa Kirin North America effective April 1, 2020; he has been a member of the Kyowa Kirin North America Board of Directors since 2019. Prior to joining Kyowa Kirin full time, Mr. Zieziula was president and managing director at EMD Serono, North America, a subsidiary of Merck KGaA, Darmstadt, Germany, where he drove the commercialization of major products and the establishment of franchises in oncology, central nervous system (CNS), immunology, fertility, and endocrinology. Mr. Zieziula's experience also includes senior commercial and sales leadership roles at AMAG Pharmaceuticals, Roche, Bristol Myers Squibb, and Merck & Co. Mr. Zieziula is a graduate of the State University of New York at Buffalo and also holds a master of business administration degree from Canisius College.
Gary Zieziula, MBA
President, North America, Director on Board of Directors
Len Paolillo
Executive Vice President, Chief Commercial Officer
Len Paolillo joined Kyowa Kirin in March 2014 and was appointed EVP and chief commercial officer in April 2019. Prior to serving as chief commercial officer for the integrated business, Mr. Paolillo served as president of Kyowa Kirin Inc and had responsibility for launching POTELIGEO® and Nourianz™ in the United States. Under his leadership, Kyowa Kirin's business has transformed to support the commercialization of novel specialty medicines and has consistently exceeded its sales and revenue targets. Mr. Paolillo started his career by designing marketing campaigns for new product launches. In 2003, he joined Warner Chilcott Inc in a sales role. As he advanced, he gained experience in a range of therapeutic areas, including oncology, CNS, dermatology, and women’s health. Mr. Paolillo also serves on the New York Advisory Council for Dream Foundation, a national foundation dedicated to fulfilling end-of-life dreams of terminally ill adults and their loved ones. Mr. Paolillo earned a bachelor’s degree in business from Manhattan College.
Len Paolillo
Executive Vice President, Chief Commercial Officer
Andrew J. McKnight, PhD
President & Chief Scientific Officer
Dr. Andrew McKnight joined Kyowa Kirin as chief scientific officer (CSO) in 2015. He currently holds the position of president and CSO at Kyowa Kirin Pharmaceutical Research. He is responsible for early-stage drug discovery within Kyowa Kirin’s Immunology & Allergy division. Dr. McKnight trained as an immunologist. He earned a doctor of philosophy degree from the University of Oxford, followed by post-doctorate work in research labs at Harvard and Oxford. He moved into the biopharma industry with Celltech in the UK (subsequently acquired by UCB) as head of molecular biology and project leader for both inflammatory disease and oncology projects. He joined Pfizer's Global R&D Division in the UK and later transferred to their site in Boston, USA. At Pfizer, Dr. McKnight managed a research group focused on the discovery of fully-human mAbs from individuals who had recovered from bacterial infections and also participated in business development activities while scouting for external scientific alliances with specialized biotechs. In 2012, Dr. McKnight joined AnaptysBio in San Diego, where he was instrumental in reinvigorating their R&D pipeline, resulting in their first independent clinical studies and a successful IPO.
Andrew J. McKnight, PhD
President & Chief Scientific Officer
Tara D’Orsi, JD
Executive Vice President, Chief Compliance Officer and General Counsel
Ms. Tara D’Orsi joined Kyowa Kirin in September 2017 and was appointed EVP, chief compliance officer and general counsel in 2019. Prior to joining Kyowa Kirin, Ms. D’Orsi was a member of the Life Sciences group at Lowenstein Sandler LLP, where she advised biotech and pharmaceutical companies on legal and compliance matters throughout a medicine's lifecycle, from development through commercialization. Throughout her career, Ms. D’Orsi has played a leadership role in providing legal and compliance advice designed to minimize risk and achieve her clients’ business objectives. She previously served as the General Counsel of Robert Wood Johnson University Hospital Rahway and spent 6 years as Senior Counsel of Reliant Pharmaceuticals, before it was acquired by GlaxoSmithKline in 2007. She began her career with a judicial clerkship in the New Jersey State Superior Court before taking positions in the Life Sciences and Healthcare groups at Gibbons PC and K&L Gates LLP.
Tara D’Orsi, JD
Executive Vice President, Chief Compliance Officer and General Counsel
Stephen Partridge
Acting, Chief Development Officer
Dr Stephen Partridge joined Kyowa Kirin in 2018 as VP and global head of Clinical Operations, responsible for the clinical trial delivery across the development phase pipeline. In June 2020, he took on an interim role with broader responsibility overseeing development in the North America and EU regions. Steve has a PhD in biochemistry from Aston University in Birmingham UK. He spent most of his career in a range of development roles at AstraZeneca in both Sweden and UK (where he worked on the development of Brilinta, and later oncology products such as Lynparza). He subsequently moved to Astellas Pharma based in Leiden, Netherlands as the Head of Clinical Science for EU development, working with a range of nephrology products such as roxadustat and also enzalutamide in prostate cancer. Steve is a board member of the Bundy Foundation, a research charity based in Lund University Sweden which aims to develop medical research talent by funding innovative research.
Stephen Partridge
Acting, Chief Development Officer
Paul Testa, MS, MBA
Executive Vice President, Supply Chain and Operations
Mr. Paul Testa joined Kyowa Kirin in 2019 as EVP for supply chain and operations. Previously, he held senior executive positions in global supply chain and operations at Shire (acquired by Takeda) and Johnson & Johnson — most recently leading 500+ professionals in 25+ countries, leading a supply chain strategic transformation, and helping Shire to grow its revenue from $3 billion to ~$15 billion. He earned a bachelor of science degree from Rensselaer Polytechnic Institute, a master of science degree from Washington University, and a master of business administration degree from Boston University.
Paul Testa, MS, MBA
Executive Vice President, Supply Chain and Operations
Ana Bastani-Posner
Executive Vice President, Chief Financial Officer
Ms. Ana Bastiani-Posner joined Kyowa Kirin in June 2020 as EVP, chief financial officer for Kyowa Kirin North America. Prior to Kyowa Kirin, Ms. Bastiani-Posner held the position of SVP, finance and administration at the New York Genome Center as a member of its executive team. In the last 20 years, Ms. Bastiani-Posner held positions of increasing responsibility in the pharmaceutical industry at Schering-Plough, Novartis and Allergan across multiple functions including R&D, G&A, commercial finance, and corporate financial planning & analysis. She developed deal models, led Merger and acquisition activities, business integration and synergy efforts through several pharmaceutical deals including the proposed mega-merger of Pfizer-Allergan. She is originally from Brazil where she began her finance career in the banking industry in 1985. She holds a bachelor's degree from the Pontifícia Universidade Católica do Rio Grande do Sul and a master of international management from Thunderbird American Graduate School of International Management.
Ana Bastani-Posner
Executive Vice President, Chief Financial Officer
Takeshi Masuda
Executive Vice President, Corporate Planning and Finance

Mr. Takeshi Masuda joined Kyowa Kirin North America in 2015, and is a member of the Board of Directors. Prior to transferring to the United States, he achieved a strong record of success working on mergers and acquisitions, business development and license-out activity, finance, and strategic planning for the life science, commodity and horticulture businesses within KIRIN group companies in US, Europe and Japan. Mr. Masuda is an experienced leader of high performing teams in multiple countries.

Takeshi Masuda
Executive Vice President, Corporate Planning and Finance
Jonathan Patroni, BS, MBA, ASQ Quality Auditor
Global Head of Quality Assurance
Mr. Jonathan Patroni joined Kyowa Kirin in 2019, bringing 25 years of experience in working for multinational, mid- and small-size pharmaceutical organizations. Mr. Patroni currently serves as the global quality assurance head, with responsibility for leading a global quality team that creates and manages strategic and operational plans, including the development of policies and practices to foster a culture of continuous improvement and high organizational standards. Prior to joining Kyowa Kirin, Mr. Patroni was quality VP for Shire. In positions with J&J and Wyeth, he managed biologics and vaccine manufacturing, technical compliance, regulatory inspections, and site compliance. He began his career in 1996 with Merck in the Site Product QA Release group. He holds a bachelor’s degree from Pennsylvania State University and a master of business administration degree from Temple University and is a certified Six Sigma Process Excellence Green Belt.
Jonathan Patroni, BS, MBA, ASQ Quality Auditor
Global Head of Quality Assurance
Paul Froisland
Senior Vice President, Human Resources
Mr. Paul Froisland is SVP of human resources at Kyowa Kirin, North America and has more than 18 years of experience in working for small to mid-sized pharmaceutical companies. Mr. Froisland joined Kyowa Kirin in 2016 and was appointed vice president of human resources for Kyowa Kirin, North America in April 2019. He has experience in senior HR leadership roles, both globally and regionally, at companies such as Organon Pharmaceuticals, Ferring Pharmaceuticals, Warner Chilcott, and Managed Healthcare Associates prior to joining Kyowa Kirin. As SVP, he plays the role of strategic advisor and business partner on all human resource–related matters and works to assist the business and employees in achieving optimal results. Mr. Froisland has a bachelor of science degree in psychology and a master of business administration degree in international business from Centenary College.
Paul Froisland
Senior Vice President, Human Resources
Snehal Shah, PharmD
Senior Vice President, Regulatory Affairs and Pharmacovigilance
Dr. Snehal Shah is SVP of Regulatory Affairs and Pharmacovigilance at Kyowa Kirin, North America. Dr. Shah has more than 15 years of global experience in regulatory science and pharmacovigilance, gained at leading pharmaceutical companies including Hoffmann La-Roche/Genentech and Noven Pharmaceuticals (member of the Hisamitsu Group). He has led biologics and small-molecule development programs in rare orphan diseases, oncology, CNS, virology, transplantation, inflammation, endocrinology, and women’s health, at all product lifecycle phases through commercialization. Most notably, Dr. Shah has provided strategic regulatory leadership to successfully bring more than a dozen market applications from filing through approval, resulting in first-in-class treatments for rheumatoid arthritis, vasomotor symptoms associated with menopause, cutaneous T-cell lymphoma, and Parkinson’s disease. Dr. Shah holds a bachelor of science degree in pharmacy from Rutgers University and a doctor of pharmacy degree from the University of Kansas. He also completed the American Course of Drug Development and Regulatory Sciences Certification program at the University of California, San Francisco.
Snehal Shah, PharmD
Senior Vice President, Regulatory Affairs and Pharmacovigilance
Naoki Sawada, RPH
Vice President, Global Product Lead for Poteligeo
Mr. Sawada leads efforts to formulate and implement the global product strategy for POTELIGEO® through all teams and operations within the United States. He also serves as a board member for the North America board of directors. Mr. Sawada's experience includes roles leading the global development of POTELIGEO® and Crysvita®, and Japanese and Asian development of NESP® in collaboration with Amgen.
Naoki Sawada, RPH
Vice President, Global Product Lead for Poteligeo
Katsuyoshi Tsukii
Vice President, Global Product Lead for istradefylline
Mr. Tsukii was appointed global product leader for istradefylline in 2019. Mr. Tsukii has worked for Kyowa Kirin in Japan for 15 years, where he served as project leader for several CNS development programs. He joined Kyowa Kirin North America in 2016, and has since taken on leadership and planning responsibilities for a global CNS development project as it progresses from development to commercialization.
Katsuyoshi Tsukii
Vice President, Global Product Lead for istradefylline

Global directors and officers

“The reason I joined this industry was for the patient – commitment to life is really the most important value to me personally. Our tagline is taking the walk of life one life at a time and making sure that we are doing the right thing for the patient.”

– Sue Smith, VP
Oncology Business Unit

“Innovation is at the forefront of everything we do; the research labs apply novel technologies, sourcing novel ideas from other academic institutions and bringing them into our organization. Of the three products that have been approved, they’ve all been first-in-class, new molecular entities.

That’s innovation.”

– Deb Braccia, VP
Medical Affairs

Contact Us

*Required

Contact Form

  • For questions related to our products, please use the links provided under Our Medicines.

By clicking the Submit button, I authorize Kyowa Kirin, Inc., its affiliates, subsidiaries, and third-party agents to contact me by mail and/or email to provide information on products, programs, services, and disease-state information and/or utilize my information for market research or analytics. Kyowa Kirin, Inc., its affiliates, subsidiaries, and third-party agents will not utilize or distribute my personal information outside the above terms of consent.